Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Up to $12.33

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) gapped up before the market opened on Friday . The stock had previously closed at $12.33, but opened at $13.07. Y-mAbs Therapeutics shares last traded at $12.88, with a volume of 11,538 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Canaccord Genuity Group boosted their price objective on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, March 4th. HC Wainwright lifted their price objective on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, May 13th. BMO Capital Markets boosted their target price on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a research report on Monday, March 4th. Finally, Truist Financial initiated coverage on shares of Y-mAbs Therapeutics in a research note on Friday. They issued a “buy” rating and a $21.00 price target for the company. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of “Hold” and an average price target of $17.86.

Y-mAbs Therapeutics Stock Performance

The stock has a 50-day moving average price of $13.07 and a two-hundred day moving average price of $12.82. The stock has a market capitalization of $530.07 million, a PE ratio of -24.65 and a beta of 0.69.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The firm had revenue of $19.93 million for the quarter, compared to analysts’ expectations of $22.06 million. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. As a group, equities analysts predict that Y-mAbs Therapeutics, Inc. will post -0.45 earnings per share for the current year.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 25,000 shares of the stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $12.00, for a total value of $300,000.00. Following the completion of the sale, the insider now owns 240,032 shares in the company, valued at approximately $2,880,384. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO Bo Kruse sold 31,371 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $12.07, for a total transaction of $378,647.97. Following the sale, the chief financial officer now owns 210,877 shares in the company, valued at $2,545,285.39. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Thomas Gad sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $12.00, for a total transaction of $300,000.00. Following the transaction, the insider now owns 240,032 shares of the company’s stock, valued at approximately $2,880,384. The disclosure for this sale can be found here. In the last quarter, insiders sold 99,444 shares of company stock valued at $1,203,925. Company insiders own 21.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

Several hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP increased its holdings in shares of Y-mAbs Therapeutics by 208.3% in the third quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock worth $748,000 after purchasing an additional 92,765 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Y-mAbs Therapeutics during the 4th quarter worth approximately $562,000. Trexquant Investment LP boosted its position in shares of Y-mAbs Therapeutics by 417.5% during the 3rd quarter. Trexquant Investment LP now owns 76,585 shares of the company’s stock valued at $417,000 after acquiring an additional 61,785 shares during the last quarter. Los Angeles Capital Management LLC grew its holdings in shares of Y-mAbs Therapeutics by 17.3% in the fourth quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock valued at $2,432,000 after purchasing an additional 52,610 shares in the last quarter. Finally, Sapient Capital LLC bought a new stake in Y-mAbs Therapeutics in the fourth quarter worth $298,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.